Direct effect of calcitriol on the regulation of parathyroid hormone secretion in a case of pseudo-hypoparathyroidism (a 24-month follow-up study)
- PMID: 7641504
- DOI: 10.1007/BF02208341
Direct effect of calcitriol on the regulation of parathyroid hormone secretion in a case of pseudo-hypoparathyroidism (a 24-month follow-up study)
Abstract
The diagnosis of pseudohypoparathyroidism with osteitis fibrosa was made in a 51-year-old woman on the basis of hypocalcaemia, elevated plasma PTH (1-84) and blunted cAMP response to hPTH infusion. Radiologically, widespread signs of hyperparathyroidism were observed and quantitative histomorphometry confirmed the increased bone cellular turnover. Treatment with calcitriol (1,25 dihydroxyvitamin D3) induced a dramatic improvement of bone lesions. During treatment PTH (1-84) normalized with high dosage of calcitriol in spite of low or subnormal levels of serum calcium, and subsequently increased for each reduction of calcitriol dosage despite normal calcium levels. Our observations support a major and direct effect of 1,25 dihydroxyvitamin D3 on the regulation of parathyroid secretion of parathyroids glands.
Similar articles
-
Renal-nonresponsive, bone-responsive pseudohypoparathyroidism. A case with normal vitamin D metabolite levels and clinical features of rickets.Am J Dis Child. 1984 Nov;138(11):1030-3. Am J Dis Child. 1984. PMID: 6548601
-
Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone.J Bone Miner Res. 1993 Jan;8(1):83-91. doi: 10.1002/jbmr.5650080111. J Bone Miner Res. 1993. PMID: 8427051
-
Inhibition of 1,25(OH)2D production by hypercalcemia in osteitis fibrosa cystica: influence on parathyroid hormone secretion and hungry bone disease.Bone Miner. 1993 Oct;23(1):15-26. doi: 10.1016/s0169-6009(08)80087-6. Bone Miner. 1993. PMID: 8274876
-
Current advances in the therapy of secondary hyperparathyroidism and osteitis fibrosa.Miner Electrolyte Metab. 1991;17(4):250-5. Miner Electrolyte Metab. 1991. PMID: 1813787 Review.
-
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
Cited by
-
Variable Bone Phenotypes in Patients with Pseudohypoparathyroidism.Curr Osteoporos Rep. 2023 Jun;21(3):311-321. doi: 10.1007/s11914-023-00787-6. Epub 2023 Apr 4. Curr Osteoporos Rep. 2023. PMID: 37014531 Review.
-
Bone mineral density in pseudohypoparathyroidism type 1a.J Clin Endocrinol Metab. 2010 Sep;95(9):4465-75. doi: 10.1210/jc.2010-0498. Epub 2010 Jul 7. J Clin Endocrinol Metab. 2010. PMID: 20610593 Free PMC article.